Effect of edaravone on T lymphocyte subsets and oxidative stress level in patients with cardiogenic cerebral embolism

摘要

Objective:To explore the effect of edaravone on T lymphocyte subsets and oxidative stress level in patients with cardiogenic cerebral embolism.Methods:A total of 100 patients with cardiogenic cerebral embolism who were admitted in our hospital from June, 2013 to June, 2015 were included in the study and randomized into the observation group and the control group. The patients in the observation group were given edaravone, while the patients in the control group were given the conventional treatments. CD4, CD8, GSH-Px, and ROS levels, the occurrence of adverse reactions, and the clinical efficacy after treatment in the two groups were observed and compared.Results:The comparison of CD4 and CD8 levels before treatment between the two groups was not statistically significant (P>0.05). After treatment, CD4 level was significantly elevated, while CD8 level was significantly reduced when compared with before treatment (P0.05). After treatment, GSH-Px level was significantly elevated, while ROS level was significantly reduced when compared with before treatment (P<0.05). The improvement of GSH-Px and ROS levels after treatment in the observation group was significantly superior to that in the control group (P<0.05). The occurrence rate of adverse reactions in the observation group was significantly lower than that in the control group, while the treatment effective rate was significantly higher than that in the control group (P<0.05). Conclusions:Edaravone in the treatment of cardiogenic cerebral embolism can effectively correct the imbalance of T lymphocyte subsets, and reduce the oxidative stress level, with less adverse reactions and significant therapeutic effect.